IP Library › Granted Patent US 12,656,357
Granted Patent B2
US 12,656,357 · App. 17/258,789 · Granted Jun 16, 2026

Methods and devices that change color to indicate the presence of opioids and other narcotics

Inventors: Abraham Joy (Copley, OH); Tanmay Jain (Akron, OH); Nicholas Nun (Akron, OH); Amal Narayanan (Cuyahoga Falls, OH); Russell Catania (Mentor, OH)
Assignee: The University of Akron
G01N33/9486G01N21/78G01N33/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,656,357
App. No.
17/258,789
Granted
Jun 16, 2026
Kind
B2
Abstract

A safe and reliable drug detection device is provided that detects the presence of opioids and other amine-containing drugs, and enables first responders, law enforcement personnel, and others to avoid inadvertent exposure to these potentially lethal drugs. The detector device includes a substrate and a dye that produces a visible color change rapidly when the device is brought into contact with an opioid or other amine-containing drug. A method for preparing the detector device and a method for detecting opioids and other amine-containing drugs on a surface are also provided.

Claims (35)

1 . A detection device for detecting a target analyte on a surface, the detection device comprising

a porous fabric substrate capable of absorbing liquid; and

a dye that produces a visible color change upon exposure to an opioid or other amine-containing drug, wherein the dye is selected from the group consisting of malachite green oxalate, brilliant green, erythrosine b, methyl green, methyl violet, picric acid, cresol red, crystal violet, m-cresol purple, thymol blue, bromocresol green, cresol red, p-xylenol blue, eosin bluish, quinaldine red, 4-(dimethylamino) azobenzol, methyl orange, 1-naphtholphthalein, m-cresol purple, thymol blue, p-xylenol blue, thymolphthalein, alkali blue, alizarin yellow gg, indigo carmine, epsilon blue, titan yellow, and bromocresol purple,

wherein the dye is either within the substrate or coated on the substrate or both within the substrate and coated on the substrate, and wherein the detection device is non-toxic to humans.

2 . The detection device of claim 1 , wherein the dye is selected from the group consisting of cresol red, m-cresol purple, bromocresol green, and bromocresol purple, wherein the amine-containing drug is characterized as one or more of a medical drug for pain relief and an illicit drug.

3 . The detection device of claim 1 , wherein the target analyte is selected from the group consisting of morphine, hydrocodone, oxycodone, fentanyl, carfentanyl, naloxone, endorphins, heroin, codeine, cocaine, and mixtures and derivatives thereof, and wherein the visible color change upon exposure to an opioid or other amine-containing drug can occur without any additional heating and without the addition of an acid or a base.

4 . The detection device of claim 1 , wherein the substrate comprises a woven fabric, a nonwoven fabric, a cellulose tissue, a paper towel, a coform material, an airlaid material, a polyester amide polymer having pendant functional groups, or a bonded-carded web, wherein the substrate is in the form of a wipe, a glove, or a swab.

5 . The detection device of claim 1 , wherein the substrate comprises natural fibers, synthetic fibers, or combinations thereof.

6 . The detection device of claim 1 , wherein the substrate comprises fibers selected from the group consisting of wood pulp, cotton, bamboo, hemp, polyolefin, polyester, polyamide, polylactic acid, rayon, lyocell, and combinations thereof.

7 . The detection device of claim 1 , wherein the substrate is in the form of a wipe, a swab, or a glove.

8 . The detection device of claim 1 , wherein the detection device further includes one or more optional ingredients selected from the group consisting of color enhancers, catalysts, mechanical property modifiers, optical brighteners, anti-static agents, flame retardants, lubricants, wetting agents, softeners, mordants, and inorganic additives.

9 . The detection device of claim 1 , wherein the detection device further comprises a wetting agent.

10 . The detection device of claim 1 , wherein the detection device is sealed in an airtight package.

11 . A method for detecting a target analyte on a surface, the method comprising

contacting a surface that is suspected of containing a target analyte with a drug detection device, where the drug detection device includes

a porous fabric substrate capable of absorbing liquid, and

a dye that is capable of producing a visible color change upon the contact with the target analyte, wherein the dye is selected from the group consisting of malachite green oxalate, brilliant green, erythrosine b, methyl green, methyl violet, picric acid, cresol red, crystal violet, m-cresol purple, thymol blue, bromocresol green, cresol red, p-xylenol blue, eosin bluish, quinaldine red, 4-(dimethylamino) azobenzol, methyl orange, 1-naphtholphthalein, m-cresol purple, thymol blue, p-xylenol blue, thymolphthalein, alkali blue, alizarin yellow gg, indigo carmine, epsilon blue, titan yellow, and bromocresol purple,

wherein the dye is either within the substrate or coated on the substrate or both within the substrate and coated on the substrate.

12 . The method of claim 11 , wherein the method further comprises applying a wetting agent to either or both of the drug detection device or the surface that is suspected of containing a target analyte, prior to the step of contacting.

13 . The method of claim 11 , further comprising steps of

providing the detection device sealed in an airtight package, prior to the step of contacting;

removing the detection device from the airtight package, prior to the step of contacting; and

visually inspecting the drug detection device after the step of contacting, to determine if any portion of the drug detection device has changed color.

14 . The method of claim 11 , wherein at least a portion of the drug detection device undergoes a visible color change within about 30 seconds of the contact with the target analyte, wherein the visible color change occurs without any additional heating and without the addition of an acid or a base.

15 . The method of claim 11 , wherein at least a portion of the drug detection device undergoes a visible color change within about 5 seconds of the contact with the target analyte, wherein the visible color change occurs without any additional heating and without the addition of an acid or a base.

16 . The method of claim 11 , wherein the dye is selected from the group consisting of cresol red, m-cresol purple, bromocresol green, and bromocresol purple.

17 . The method of claim 11 , wherein the target analyte is an amine-containing drug, and wherein the method does not require a user to pick up the target analyte, wherein the amine-containing drug is characterized as one or more of a medical drug for pain relief and an illicit drug.

18 . The method of claim 11 , wherein the target analyte is selected from the group consisting of morphine, hydrocodone, oxycodone, fentanyl, carfentanyl, naloxone, endorphins, heroin, codeine, cocaine, and mixtures and derivatives thereof.

19 . The method of claim 11 , wherein the substrate comprises a woven fabric, a nonwoven fabric, a cellulose tissue, a paper towel, a coform material, an airlaid material, a polyester amide polymer having pendant functional groups, or a bonded-carded web.

20 . A detection device for detecting a target analyte on a surface, the detection device comprising

a substrate, wherein the substrate is selected from the group consisting of a wipe, a glove, and a swab; and

a dye that produces a visible color change upon exposure to an opioid or other amine-containing drug, wherein the dye is selected from the group consisting of malachite green oxalate, brilliant green, erythrosine b, methyl green, methyl violet, picric acid, cresol red, crystal violet, m-cresol purple, thymol blue, bromocresol green, cresol red, p-xylenol blue, eosin bluish, quinaldine red, 4-(dimethylamino) azobenzol, methyl orange, 1-naphtholphthalein, m-cresol purple, thymol blue, p-xylenol blue, thymolphthalein, alkali blue, alizarin yellow gg, indigo carmine, epsilon blue, titan yellow, and bromocresol purple,

wherein the dye is either within the substrate or coated on the substrate or both within the substrate and coated on the substrate,

wherein the detection device is non-toxic to humans, and

wherein the visible color change upon exposure to an opioid or other amine-containing drug can occur without any additional heating and without the addition of an acid or a base.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2021
From: JOY, ABRAHAM; JAIN, TANMAY; NUN, NICHOLAS; NARAYANAN, AMAL; CATANIA, RUSSELL
To: THE UNIVERSITY OF AKRON
Reel/Frame 056068/0657 →
Continuity (2)
Provisional Application 62696484 · Jul 11, 2018
Related Publication 20210302446A1 · Sep 30, 2021
References Cited (51)
US 3485706A · Evans · 1969 [cited by applicant]
US 3620903A · Bunting, Jr. et al. · 1971 [cited by applicant]
US 3849241A · Butin et al. · 1974 [cited by applicant]
US 4100324A · Anderson et al. · 1978 [cited by applicant]
US 4340563A · Appel et al. · 1982 [cited by applicant]
US 4443513A · Meitner et al. · 1984 [cited by applicant]
US 4511488A · Matta · 1985 [cited by applicant]
US 4548856A · Ali Khan et al. · 1985 [cited by applicant]
US 4775582A · Abba et al. · 1988 [cited by applicant]
US 4833003A · Win et al. · 1989 [cited by applicant]
US 4853281A · Win et al. · 1989 [cited by applicant]
US 5009747A · Viazmensky et al. · 1991 [cited by applicant]
US 5284703A · Everhart et al. · 1994 [cited by applicant]
US 5350624A · Georger et al. · 1994 [cited by applicant]
US 5382400A · Pike et al. · 1995 [cited by applicant]
US 5575874A · Griesbach, III et al. · 1996 [cited by applicant]
US 5667635A · Win et al. · 1997 [cited by applicant]
US 6200669B1 · Marmon et al. · 2001 [cited by applicant]
US 6224977B1 · Kobylivker et al. · 2001 [cited by applicant]
US 6750163B2 · Wang et al. · 2004 [cited by applicant]
US 6811638B2 · Close et al. · 2004 [cited by applicant]
US 6946413B2 · Lange et al. · 2005 [cited by applicant]
US 6960371B2 · Bunyard et al. · 2005 [cited by applicant]
US 9593201B2 · Joy et al. · 2017 [cited by applicant]
US 20040192136A1 · Gusky et al. · 2004 [cited by applicant]
US 20060008621A1 · Gusky et al. · 2006 [cited by applicant]
US 20100197516A1 · Holmes · 2010 [cited by applicant]
US 20110151596A1 · Cho · 2011 [cited by applicant]
US 20110159596A1 · Keinan · 2011 [cited by examiner]
US 20170233912A1 · Kellner et al. · 2017 [cited by applicant]
hhs.gov/opioids. [Online). Available: https://www.hhs.gov/opioids/about-theepidemic/index.html. [Accessed: Sep. 7, 2018). [cited by applicant]
Opioid Overdoses Treated in Emergency Departments. [Online). Available: https://www.cdc.gov/vitalsigns/opioid-overdoses/. [Accessed: Sep. 7, 2018). [cited by applicant]
B. Medsker, E. Fomo, H. Simhan, C. Juan, and R. Sciences, “The Economic Burden of Prescription Opioid Overdose, Abuse and Dependone in the United States, 2013,” Med. Care, vol. 54,No. 10,pp. 901-906,2016. [cited by applicant]
M. P. Prekupec, P. A. Mansky, and M. H. Baumann, “Misuse of Novel Synthetic Opioids: A Deadly New Trend,” J. Addict. Mad., vol. 11, No. 4, pp. 256-265, 2017. [cited by applicant]
J. K. O'Donnell, J. Halpin, C. L. Mattson, B. A. Goldberger, and R. M. Gladden, “Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 -10 States, Jul.-Dec. 2016,” MMWR. Morb. Morla/. Wk/y. Rep., vol. 66, No. 43, pp.… [cited by applicant]
“Morbidity and Mortality Weekly Report (MMWR).” [Online). Available: https://www.cdc.gov/mmwr/volumes/65/wr/mm6533a2.htm. [Accessed: Sep. 7, 2018). [cited by applicant]
J. K. O'Donnell, R. M. Gladden, and p. Seth, “Trends in Deaths Involving Heroin and Synthetic Opioids Excluding Methadone, and Law Enforcement Drug Product Reports, by Census Region—United States, 2006-2015,” MMWR. Morb… [cited by applicant]
“Fentanyl FAQs.” [Online]. Available: https:llwww.dea.gov/druginfo/fentanyl-faq.shtml. [Accessed: Sep. 7, 2018]. [cited by applicant]
P. Armenian, K. T. Vo, J. Barr-Walker, and K. L. Lynch, “Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review,” Neuropharmacology, vol. 134, pp. 121-132, 2018. [cited by applicant]
K. Tsujikawa et al., “Development of an on-site screening system for amphetamine-type stimulant tablets with a portable attenuated total reflection Fourier transform infrared spectrometer,” Anal. Chim. Acta, vol. 608, N… [cited by applicant]
N. W. Tumer, M. Cauchi, E. V. Piletska, C. Preston, and S. A. Piletsky, “Rapid qualitative and quantitative analysis of opiates in extract of poppy head via FTIR and chemometrics: Towards in-field sensors,” Biosens. Bio… [cited by applicant]
“Powerful detection technology.” [Online]. Available: https:llcen.acs.org/articles/95/i451P0werful-detection-technology-powerful-new.html. [Accessed: Sep. 7, 2018]. [cited by applicant]
K. E. Toole, S. Fu, R. G. Shimmon, N. Kraymen, and S. Taflaga, “Color Tests for the Preliminary Identification of Methcathinone and Analogues of Methcathinone,” Microgram J., vol. 9, No. 1, pp. 27-32, 2007. [cited by applicant]
K. M. Agg, A. F. Craddock, R. Bos, P. S. Francis, S. W. Lewis, and N. W. Bamett, “A rapid test for heroin (3,6-diacetylmorphine) based on two chemiluminescence reactions,” J. Forensic Sci., vol. 51, No. 5, pp. 108˜1084,… [cited by applicant]
N. A. dos Santos et a/. , “Evaluating the selectivity of colorimetric test (Fast Blue BB salt) for the cannabinoids identification in marijuana street samples by UV-Vis, TLC, ESI(+)FT-ICR MS and ESI(+)MS/MS,” Forensic C… [cited by applicant]
M. Philp and S. Fu, “A review of chemical ‘spot’ tests: A presumptive illicit drug dentification technique,” Drug Test. Anal., vol. 10, No. 1, pp. 95-108, 2018. [cited by applicant]
C. L. O'Neal, D. J. Crouch, and A. A. Fatah, “Validation of Twelve Chemical Spot Tests for the Detection of Drugs of Abuse,” Encycl. Forensic Sci. Second Ed., vol. 109, pp. 38˜387, 2012. [cited by applicant]
N. Goonoo, A. Bhaw-Luximon, R. Ujoodha, A. Jhugroo, G. K. Hulse, and D. Jhurry, “Naltrexone: A review of existing sustained drug delivery systems and emerging nanabased systems,” J. Control. Release, vol. 183, No. 1, pp… [cited by applicant]
S. D. Comer, M. A. Sullivan, and G. K. Hulse, “Sustained-release naltrexone: novel treatment for opioid dependence. [Review] [105 refs],” Expert Opin. Investig. Drugs, vol. 16,No. 8,pp. 1285-1294, 2007. [cited by applicant]
P. Lobmaier, M. Gossop, H. Waal, and J. Bramness, “The pharmacological treatment of opioid addiction—a clinical perspective,” Eur. J. Clin. Pharmacol., vol. 66, No. 6, pp. 537-545, 2010. [cited by applicant]
“Emerging Trends and Alerts.” [Online). Available: https:llwww.drugabuse.gov/drugsabuselemerging-trends-alerts. [Accessed: Sep. 7, 2018). [cited by applicant]